Karuna Therapeutics, Inc. (KRTX) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Boston, MA, 美国. 現任CEO為 William Meury.
KRTX 擁有 IPO日期為 2019-06-28, 339 名全職員工, 在 NASDAQ Global Market, 市值為 $12.6B.
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines for psychiatric and neurological disorders. The company's lead product candidate, KarXT, is an oral muscarinic receptor modulator currently in Phase III clinical trials for treating acute psychosis in schizophrenia patients, as well as negative and cognitive symptoms associated with schizophrenia, psychosis, and dementia-related psychosis. Karuna has established strategic partnerships with major pharmaceutical and research organizations, including Eli Lilly and Company, Zai Lab, PureTech Health, Charles River Laboratories, and PsychoGenics, Inc. Based in Boston, Massachusetts, the company was incorporated in 2009 and rebranded as Karuna Therapeutics in 2019 to reflect its expanded therapeutic focus.
